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Viral hepatitis is a global threat for public health 
and one of the leading causes of mortality and 
disabilities worldwide (1, 2). Despite a decline in 
the number of deaths caused by most communi-
cable diseases, hepatitis mortality rate had an in-
creasing trend worldwide and changed from 0.89 
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Background: This study aimed at estimating the incidence, mortality, and burden of Hepatitis B (HBV) and 
Hepatitis C (HCV) viruses and their trends from 2008 to 2015. 
Methods: The Disability Adjusted Life Year (DALYs) index was applied to calculate the burden of the diseases 
by age, sex, time, and locations. The incidence and demographic data were obtained from HBV and HCV sur-
veillance system, and the data on natural history was extracted from the cohort studies; moreover, the data on 
the standard life expectancy was obtained from the Iranian life table 2016. The two values of 0.03 and 21.5 yr 
were set as the discount rate and mean standard duration of the disease for both types of hepatitis.  
Results: The burden of HBV decreased from 13735 to 78277.6 yr, but there was an increase in the burden of 
HCV from 5174 to 14395 yr over the studied period. The burden of both types of hepatitis was higher among 
males than females. The incidence of HBV increased from 46611 to 22996 cases, and the incidence of HCV 
increased from 1210 to 3939 cases. The HBV decreased from 1925 to 1394 cases; however, the number of 
deaths caused by HCV increased from 197 to 583 cases over the studied period. The share of YLLs raised from 
5% to 10% for HBV whereas it changed from 23% to 62% for HCV over the studied years. Tehran, Khorasan 
Razavi, and Golestan had the highest and Chaharmahal and Bakhtiari, Kurdistan, and Kermanshah had the 
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Conclusion: Although the incidence, mortality, and burden of HBV declined over the eight studied years, 
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million in 1990 to 1.45 million in 2013 (1,2). Dur-
ing the same period of time, its Disability Adjust-
ed Life Years (DALYs) raised from 31.7 to 42.5 
million, respectively. Viral hepatitis was the 22nd 
leading cause of DALYs in 1990 and 18th in 
2013 (1). Hepatitis B virus (HBV) and Hepatitis 
C virus (HCV) are the main causes of the high 
burden of hepatitis worldwide (3-5); they account 
for 96% of the total hepatitis mortality rate. Alt-
hough HCV is a global concern, Eastern Medi-
terranean and European countries are the most 
contaminated areas in the world. The prevalence 
of HCV is 2.3% and 1.5% in the mentioned are-
as, respectively (6). In 2015, the number of peo-
ple infected by HBV and its mortality, respective-
ly, were 257 million and 887 thousand across the 
world (7). 
Iran, with a prevalence rate of below 1%, is con-
sidered as a country with a low HCV infection, as 
compared with other countries. However, the 
epidemiological status of HCV is changing in 
Iran and its infection is increasing due to an in-
crease in the number of injecting drug users. The 
prevalence of HCV is significantly different in 
various areas of Iran, ranging from 0.05% to 
2.3% (8). In 1979, the prevalence of HBsAg 
ranged from 2.5% to 7.2% in Iran (9). The num-
ber of people infected with HBV before and after 
2010 was 2.9% and 1.3%, respectively (10). Over 
the past two decades, the epidemiological status 
of HBV has changed and started to decline due 
to the implementation of a national vaccination 
plan for infants since 1993. In 2005, the coverage 
of HBV vaccination reached 94% (11). In 2002, 
the National Hepatitis Committee expanded the 
coverage of vaccination to cover people aged 25 
yr (12). 
With the approval of the Sustainable Develop-
ment Resolution 2030, more attention has been 
paid to Hepatitis diseases (6). In 2016, the world 
health assembly approved the first "Global 
Health Sector Strategy (GHSS) on Viral Hepati-
tis, 2016-2021, with a particular focus on HBV 
and HCV". The main goals of this strategy are to 
reduce the new cases of infections by 90% and 
reduce mortality rate by 65% by 2030. This strat-
egy focuses more on HBV and HCV due to their 
high burdens (13). 
HBV and HCV include all cases of liver disorders 
diagnosed positive by HBV Surface Antigen 
(HBsAg) and HCV Antibody (Hcv Ab) tests, re-
spectively. The HCV and HBV codes are B18.2 
and B19.10, respectively.  
Estimating the burden of a disease can be useful 
for planning, controlling, and monitoring that dis-
ease. It helps to observe and judge the success of a 
country's health system in controlling and manag-
ing hepatitis over time. In line with this and in or-
der to depict a comprehensive picture of the dis-
ease over the time, we aimed at estimating the 
burden of HBV and HCV at national and provin-
cial levels to provide evidence-based strategies and 





Data on the distributions of HBV and HCV by 
sex, age, location, and time over 2008-2015 were 
obtained from the Hepatitis surveillance system. 
The data had been collected by health centers 
across the country. Comparing the recorded num-
ber of the patients with the prevalence and inci-
dence rates reported in many systematic review 
studies, there was an underestimation in the avail-
able data (14-18); accordingly, the data on HBV 
and HCV were underestimated by 9.38 and 11.36 
times. Therefore, we applied the corrected inci-
dence rates in our calculations and assumed no 
change in sex and age distributions of the diseases.  
 
Calculation of DALYs  
DALYs is calculated through adding Years of 
Life Lost due to premature death (YLLs) to 
Years of Life Lost due to disability (YLDs) (19). 
DALYs index was calculated using the National 
Burden of Disease formula developed by the 
WHO (20). We did not include age weights in 
our calculations; however, a discount rate of 0.03 
was applied for discounting health values in fu-
ture years. YLDs is calculated through multiply-
ing annual incidence rate of the diseases by the 
related median periods and its disability weights. 
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HBV and HCV not only have the same natural 
course of disease lasting 21.5 yr (21) but they also 
impose the same disease weight on the patients. 
However, the disease weight varies by age: 0.17 for 
0-4 age group, 0.181 for 5-14 age group, 0.209 for 
15-44 age group, and 0.212 for >45 age group 
(22). DALY, YLL, and YLD were calculated and 
reported by sex, age, time, and place for all the 
provinces of Iran. For each age group, the mean 
age of the members in that group was considered 
as the mortality age for patients died from hepati-
tis. However, as suggested by the WHO, the mean 
mortality age for age groups 0-1 and 1-5 was set at 
0.1 and 2.6, respectively. The standard life expec-
tancy for each age group was calculated using the 
life tables of Iranians reported by the WHO (23). 
We did not access the incidence rates of HBV 
and HCV for all years of the study. To overcome 
this problem, we extracted the prevalence rate of 
the diseases in the first (2008) and the last (2015) 
years under the study using the available system-
atic reviews (14-18) and calculated the related 
incidence rates through dividing the prevalence 
rates by 21.5 as the median value for the diseases 
duration (21). Finally, the rates of incidence in 
other years were calculated by assuming that the 
changes during the years of the study were con-
stant and had a linear trend (24-25).  
The data on the population of the country and its 
provinces in 2015 was taken from the Statistical 
Center of Iran. In order to estimate the popula-
tion of the country in previous years, the average 
growth rate of 0.021 was used. The data were 




Table 1 presents the burden of HBV by sex over the 
studied period. The disease imposes a higher burden 
on males than females. Its burden among males de-
creased from 78343 DALYs in 2005 to 43003 
DALYs in 2015. We observed the same trend for 
females, with a reduction from 59007 DALYs in 
2005 to 35275 DALYs in 2015. Overall, the adjusted 
burden of the disease decreased from 1.9 to 
0.99/1000 population over the studied period. 
Table 2 presents the burden of HCV by sex over 
the studied years. In line with an increase in its 
incidence rate over the studied years, its burden 
and mortality also increased simultaneously. 
These values have always been higher in males 
than in females. 
 
Table 1: Burden of HBV by gender over the study period 
 





















2015 686 279 43002.8 38274.8 78277.6 0.994 
(0.89-1.10) 
22996 
2014 622 274 49312.1 41950.2 91262.3 1.117 
(0.99-1.35) 
27739 
2013 993 392 62206.4 49641.8 111848.2 1.454 
(1.28-1.63) 
34235 
2012 1487 284 70797.6 56520.5 127318.1 1.674 
(1.36-1.99) 
39807 
2011 1484 393 70882.8 58149.5 129032.3 1.717 
(1.50-2.10) 
41265 
2010 1193 467 83333.6 64813.1 148146.7 1.998 
(1.76-2.23) 
48264 
2009 1939 968 74680.5 57268.4 131848.9 1.801 
(1.35-2.25) 
43840 
2008 1257 668 78343.0 59007.0 137350.0 1.901 
(1.56-2.224) 
46611 
* DALYs: Disability Adjusted Life Years, CI: Confidence Interval 
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Table 2: Burden of HCV by gender over the study period 
 



















2015 480 103 12093 2302 14395 0.196 
(0.17-0.22) 
3939 
2014 478 80 13703 2443 16145 0.238 
(0.21-0.27) 
3523 
2013 389 72 12284 2426 14711 0.198 
(0.16-0.23) 
3116 
2012 480 32 11947 1769 13716 0.249 
(0.20-0.28) 
2718 
2011 486 64 11129 1755 12884 0.222 
(0.18-0.26) 
2330 
2010 353 46 9913 1435 11347 0.216 
(0.17-0.26) 
1947 
2009 440 57 12994 1802 14796 0.298 
(0.25-0.35) 
1574 
2008 177 20 4625 549 5174 0.103 
(0.08-0.12) 
1210 
* DALY: Disability Adjusted Life Years, CI: Confidence Interval 
 
Female and male mortality rates caused by HBV de-
creased over the studied years. However, HCV mortali-
ty rate had an increasing trend. Moreover, male mortali-
ty rate did not change significantly after 2009 whereas it 
had a steady increase among females (Fig. 1). 
Fig. 2 shows the changes in the burden of HBV 
and HCV by adjusted population. The burden of 
HBV deceased among both males and females 
over the studied period, whereas the burden of 




Fig. 1: Trend of HBV (A) and HCV (B) mortality rates; 2005-2015 
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Fig. 2: DALYs attributable to HBV (A) and HCV (B) by sex; 2005-2015 
 
YLLs increased from 5% to 10% for HBV and 
23% to 62% for HCV over the studied period 
(Fig. 3). Figure 4 shows YLLs and YLDs for 
HBV and HCV by age groups. People in 30-44 
and >70 age groups had the highest YLDs and 
YLLs, respectively. The lowest burden of the dis-
ease was observed in <15 and 30-44 age groups. 
Moreover, 45-59 and 60-69 age groups had the 
highest burden of HCV. On the other hand, <29 
age group had the lowest burden of HCV. The 
highest YLLs and YLDs were observed in 60-69 
and 30-44 age groups, respectively. 
 
 
Fig. 3: YLLs, YLDs, and DALYs attributable to HBV (A) and HCV (B); 2005-2017 
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Fig.4: Burden of HBV (A) and HCV (B) by sex and age; 2015 
 
Tehran (0.259), Khorasan Razavi (0.114), and 
Golestan (0.104) had the highest adjusted burden 
of HBV per 1000 population. On the other hand, 
Chaharmahal and Bakhtiari (0.0107), Kurdistan 
(0.109), and Kermanshah (0.0122) had the lowest 
burden of HBV. Provinces with invalid data are 
colored white in the map. Since we did not have 
access to valid and reliable data on the geograph-
ical distribution of HCV (in all the years of the 
study) and HBV (in all the years of the study, ex-
cept for 2015), therefore it was not possible to 
depict the geographical distribution in the men-




Fig. 5: Geographical distribution of adjusted burden of HBV per 1000 population; 2015 
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Discussion  
 
According to the results of our study, the inci-
dence, mortality and burden of HBV decreased 
dramatically in both sexes and all age groups. 
Adjusted burden of HBV decreased from 1.9 to 
0.99 per 1000 population over the studied period. 
However, the results showed a completely oppo-
site trend for HCV. The incidence, mortality, and 
burden of HCV increased constantly over the 
studied period and its adjusted burden raised 
from 0.1 to 0.19 per 1000 population. 
The HBV mortality rate reduced by 45.5% and 
58.2% among males and females, respectively. 
However, the mortality rate among males was 
still 2.5 times more than that among females. 
Such positive changes resulted in a reduction in 
the adjusted and crude burden of the disease by 
48% and 43%, respectively over the eight years 
under the study. However, the burden of HBV 
among males was higher than that among wom-
en, however, the gap between them was reduced. 
Moreover, the crude burden of HBV among 
males and females decreased by 45% and 40%, 
respectively. Such a reduction in the burden of 
HBV was due to a dramatic decrease in new cas-
es of HBV which in turn reduced the mortality 
rate after the implementation of the HBV vac-
cination program for infants and family members 
of people living with HBV since 1994 (26). 
The results of assessing epidemiological indices 
of HCV and HBV are quite the opposite. The 
incidence and mortality of HCV increased by 
225% over the studied period. It killed more fe-
males than males. Its mortality rate among males 
and females increased by 177% and 415%, re-
spectively. However, the mortality rate among 
males was 4.7 times higher than that among 
women. Such epidemiological changes resulted in 
an increase of 90% in the adjusted burden of the 
disease and an increase of 278% in the crude 
burden of the disease over the eight studied 
years. The disease burden among females and 
males increased by 319% and 161%, respectively. 
The observed increase is attributed to an increase 
in risky behaviors such as injecting drug use and 
unsafe drug injection (27). 
Considering the results obtained for both HBV 
and HCV, the share of YLLs in the burden of 
HCV was six times more than that in the burden 
of HBV. HCV is responsible for a higher rate of 
mortality among the studied population. Howev-
er, the share of YLLs in the total burden of both 
types of hepatitis declined over time. It declined 
by half and a one-third for HBV and HCV, re-
spectively. It can indicate that the Iranian health 
system had been successful in diagnosing the dis-
ease faster and treating it more effectively (28) 
With an increase in the age of the population, the 
share of YLLs from the total burden of both 
types of hepatitis increased among both males 
and females. In >70 age group, the share of 
YLLs in the total burden of HBV was higher 
than the share of YLDs; however, in all age 
groups over 45 yr old the share of YLLs in the 
total burden of HCV was higher than the share 
of YLDs, which was due to an increase in the 
mortality rate with increasing people’s age. The 
highest burden of HBV and HCV was mainly 
observed among the two age groups of 15-60 and 
30-70 yr old, respectively. Therefore, the best ap-
proach for controlling and reducing the burden 
of hepatitis is to prevent the incidence of disease, 
especially among high-risk groups, diagnose and 
treat the disease faster, which can reduce the 
mortality rate and, finally, control the burden of 
the disease.  
The distribution map for the adjusted burden of 
HBV by population indicates that eastern and 
northeast provinces, including Khorasan Razavi, 
Golestan, and Sistan and Baluchestan are the 
main centers for this disease. Sharing borders 
with Afghanistan and Tajikistan, as the countries 
with a high prevalence of HBV, is the main rea-
son for such a difference in the distribution of 
the disease in the country (29). 
According to the results of GBD studies, HBV 
and HCV, respectively, imposed 24513 and 560 
DALYs on Iranian population in 2016, which is 
far less than what was observed in our study (1). 
In fact, the number of deaths caused by both 
types of hepatitis was underestimated by the 
GBD studies because their results were based on 
the data published by secondary studies.  
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DALYs/1000 population attributable to HBV 
varies across the world. For instance, it was 10.34 
in Germany (30), 20.4 in Spain (31), 17 in Santa 
Catharina state in Brazil (32), 63.4 in Guangdong 
(33), and 230 in Shandong in China (34). In Bra-
zil, the burden of HBV decreased between yr 
2005 to 2010 (32) which is in line with the results 
of studies in Iran. In all previous studies, the 
burden of HBV among males was higher than 
that among females. This finding is in consistent 
with the results of our study.  
There is a limited number of studies estimated 
the burden of HCV. According to the GBD 
study in 2016, HCV caused only 560 DALYs, 
0.69 DALYs per 100000 population, in Iran, 
which is far less than what is reported in our 
study. However, similar to our study, they report-
ed an ascending trend for HCV (1). Other studies 
have reported 134.5 DALYs per 100000 popula-
tion in European countries and 90.8 DALYs per 
100000 population in Spain (31), both of which 
are higher than what is reported in our study.  
As an important strength, our study used a na-
tional and sub-national individual-based panel 
data collected over eight years to detect age and 
sex differences between patients with HBV and 
HCV. However, the main limitation of the pre-
sent study was the incomplete and weak coverage 
of hepatitis registration and detection systems.  
 
Health policy implications 
In order to control and change the trend of the 
HCV burden, it is highly recommended to con-
sider the following items: reduce unnecessary in-
jections in health centers, train healthcare staff to 
ensure safe injections, train and inform drug ad-
dicts about the transmission of disease through 
injections, better manage dialysis patients and 
people with HIV/AIDS, and increase the cover-
age of HCV diagnostic tests, especially for vul-
nerable groups. Obviously, the most efficient way 
to reduce the burden of disease is to prevent and 
decrease the incidence of the disease. An im-
portant measure for preventing HCV is to reduce 
its reservoirs in the society which can be best 
done through treating patients with HCV, espe-
cially the vulnerable groups. Our results revealed 
the success of vaccination program in controlling 
HBV; therefore, it is necessary to continue cur-
rent polices; in addition, to increase the effective-
ness, health authorities should expand the cover-




Although the incidence, mortality, and burden of 
HBV declined over the eight studied years, these 
values increased dramatically for HCV. There-
fore, it is highly recommended to redistribute the 
health resources to detect patients, control the 
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